Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17269422 | 0.78 | PDE3B (0.37) | PDE3BPDE3A | |
| SCHEMBL18237511 | 0.76 | PDE3B (0.34) | PDE3BPDE3A | |
| SCHEMBL2738987 | 0.74 | PARP1 (0.35) | — | |
| SCHEMBL18237769 | 0.73 | PDE3B (0.37) | PDE3BPDE3A | |
| SCHEMBL18237891 | 0.69 | DRD2 (0.31) | PDE3BPDE3A | |
| SCHEMBL27051279 | 0.67 | ADRB1 (0.36) | PDE3BPDE3A | |
| SCHEMBL27443119 | 0.67 | ADRB1 (0.34) | — | |
| SCHEMBL18237622 | 0.66 | PDE7B (0.31) | — | |
| SCHEMBL27452711 | 0.65 | ADRB1 (0.33) | PDE3BPDE3A | |
| SCHEMBL27051433 | 0.64 | KDM5B (0.34) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8153639-B2 | kinase inhibitor; immunotherapy; viricides; function or behavior associated with PI3 kinase such as cancer, immune, cardiovascular, nervous system, metabolism/endocrine and neurological diseases, viral infection, inflammation; 3-(4-Pyridin-4-yl-thieno[3,2-d]pyrimidin-2-yl)-phenol | F. HOFFMAN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3CD | PDE3B 548/4885PDE3A 690/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | PDE3B 3089/4885PDE3A 2482/4885 |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PDE3B 1701/4885PDE3A 1396/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PDE3B 1701/4885PDE3A 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.